Abstract: A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide sequence corresponding to the amino acid sequence of the E7 peptide is shown as SEQ. ID. NO.1.

Abstract: The present invention provides a PRRSV subunit vaccine comprising a fusion protein having neutralization titers evoked, PE-PQGAB-K3, which comprises a chimeric polypeptide containing N-terminal portions of PRRSV ORF5 and ORF6 structure proteins; a portion of Pseudomonas exotoxin A binding and translocation domain; and a carboxyl terminal domain containing KDEL-KDEL-KDEL(K3) sequence. Less inflammation of PE-PQGAB-K3 vaccine group in their lungs post being PRRSV-challenged indicates that PQGAB without an antigen-specific allergy effect. Importantly, PE-PQGAB-K3 vaccine presents a good protection against PRRSV infection than control groups in pig challenged experiment.

Abstract: The present invention relates to a preparation method of protein vaccines, and comprises the steps of: (a) providing at least one amino acid sequence of an epitope of a target antigen protein; (b) converting the amino acid sequence into a nucleic acid sequence and modifying the codons; (c) synthesising a plurality of primers of the modified nucleic acid sequence; (d) synthesising the modified nucleic acid sequence in vitro; (e) inserting the synthesized fragment of the modified nucleic acid sequence into a plasmid; (f) transforming the plasmid into a host cell to produce the modified nucleic acid encoded epitope peptide; and (g) collecting and purifying the produced peptide.

Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment encoding a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid of the peptide fragment encoding the partial SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The present invention further relates to DNA sequences encoding the partial SARS E2 spike protein includes SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, or SEQ ID NO.8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.

Abstract: A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide sequence corresponding to the amino acid sequence of the E7 peptide is shown as SEQ. ID. NO.1.